Hua Medicine is a clinical-stage, innovative drug development company in China.
Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 27, 2018 | Series D | $117.40M | 1 | — | — | Detail |
Apr 21, 2016 | Series C | $50M | 1 | — | — | Detail |
Jan 8, 2015 | Series B | $25M | 1 | — | — | Detail |
Sep 20, 2011 | Series A | $50M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Venture Partners | — | Series D |
Sino-Alliance International Ltd | — | Series A |